IRCT20200105046010N45招募中未知
In- Vivo Bioequivalence study of Bicalutamide tablet 150 mg Sobhan Oncology (Bicalutamide 150mg) with brand drug (CASODEX® 150 mg AstraZeneca ) in Iranian healthy volunteers
Sobhan Oncology Pharmaceutical CO.0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index between18-28
- •Informed consent
- •Being at the age of 18-60 years old
排除标准
- •History of cardiovascular disease
- •History of liver or kidney disease
- •Alcohol & Drug addiction
- •History of hypersensitivity
研究者
相似试验
尚未招募
Unknown
Bioequivalence study of Bicalutomide 50 mgIRCT20220111053692N15Iran Hormone pharmaceutical Co.24
已完成
不适用
A clinical study of generic drug of bicalutamide on the efficacy and the safety in prostate cancer patientsProstate cancerJPRN-UMIN000005630Biwako health and welfare consortium60
已完成
不适用
Comparative fasting bioavailability of 2 different betahistine dihydrochloride 24-mg tablets: a single-dose, randomized-sequence, open-label, 2-period crossover study in healthy Thai volunteers.healthy volunteersbetahistine dihydrochlorideBioequivalenceTCTR20151106002Somruedee Chatsiricharoenkul24
终止
1 期
Bioequivalence of Bicalutamide New Formulation in JapanHealthyNCT01416870AstraZeneca102
尚未招募
不适用
enalidomide tablet 25mg ABIDI (MYLODEQ® 25mg), In-Vivo Bioequivalence in iranian healthy volunteer, In-Vivo Bioequivalence in iranian healthy volunteerIn this study the bioequivalence of test and brand of Lenalidomide tablet will evaluated..IRCT20200105046010N6Tabriz University of Medical Sciences24